Sugi Predict

Sugi Predict / Compounds / SCHEMBL6575441

SCHEMBL6575441

SCHEMBL6575441

CC(C)(C)OC(=O)CNC(=O)CNC(=O)CN

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.38
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ PTPRC P08575 2/20 0.35
▸ GAA P10253 2/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ TERT O14746 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ DGAT1 O75907 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TET2 Q6N021 1/20 0.31
▸ APLNR P35414 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13292141 1.00 RECQL (0.38) RECQLMAOAMAOBPTPRCGAA
Hydrochloric Acid SCHEMBL9087860 0.98 RECQL (0.37) RECQLMAOAMAOBPTPRCGAA
SCHEMBL2558596 0.96 RECQL (0.41) RECQLMAOAMAOBPTPRCGAA
Hydrochloric Acid SCHEMBL715683 0.94 RECQL (0.39) RECQLMAOAMAOBPTPRCGAA
SCHEMBL1119918 0.88 RECQL (0.37) RECQLMAOAMAOBGAACA12
SCHEMBL27601805 0.83 RECQL (0.33) RECQLMAOAMAOBPTPRCHRH3
SCHEMBL23332545 0.82 TDP1 (0.46) RECQLMAOAMAOBGAACA12
SCHEMBL21320375 0.82 RECQL (0.39) RECQLMAOAMAOBPTPRCGAA
SCHEMBL30099494 0.82 MAOA (0.49) MAOAMAOBGAACA12CA2
SCHEMBL30046593 0.82 RECQL (0.57) RECQLGAACA12CA2TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 — — EP disclosed
WO-2024239281-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 — — WO disclosed
EP-4426741-A1 BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE Hangzhou DAC Biotech Co., Ltd. (CN) 2024-09-11 — — EP disclosed
EP-4426729-A1 SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE Hangzhou Dac Biotech Co., Ltd. (CN) 2024-09-11 — — EP disclosed
CN-118434765-A BCMA monoclonal antibodies and antibody-drug conjugates 杭州多禧生物科技有限公司 2024-08-02 — — CN disclosed
CN-118215676-A Specific conjugation of antibody drug conjugates 杭州多禧生物科技有限公司 2024-06-18 — — CN disclosed
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-07-27 — — US disclosed
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-07-27 — — US disclosed
WO-2023078273-A1 SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-05-11 — — WO disclosed
WO-2023078021-A1 BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-05-11 — — WO disclosed
US-20170340748-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2017-11-30 — — US disclosed
US-9669102-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2017-06-06 — — US disclosed
US-20160082114-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2016-03-24 — — US disclosed
US-20150359904-A1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS IMMUNOGEN, INC. 2015-12-17 — — US disclosed
CN-1219551-C Conjugates made of metal complexes and oligonucleotides SCHERING AG (DE) 2005-09-21 — — CN disclosed
EP-0777498-B1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES SCHERING AG (DE) 2004-04-28 — — EP disclosed
US-20020077306-A1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2002-06-20 — — US disclosed
CN-1152879-A Conjugates made of metal complexes and oligonucleotides SCHERING AG (DE) 1997-06-25 — — CN disclosed
EP-0777498-A1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES SCHERING AKTIENGESELLSCHAFT (DE) 1997-06-11 — — EP disclosed
WO-1996002274-A1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES SCHERING AKTIENGESELLSCHAFT (DE) 1996-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150359904-A1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS CD47, PAICS, MCL1 RECQL 1987/4885MAOA 3548/4885MAOB 2547/4885
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 RECQL 3762/4885MAOA 1599/4885MAOB 841/4885
US-20160082114-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 RECQL 3762/4885MAOA 1599/4885MAOB 841/4885
US-20170340748-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 RECQL 3762/4885MAOA 1599/4885MAOB 841/4885
US-20020077306-A1 CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION DCLRE1B, RNASE1, DCLRE1A RECQL 739/4885MAOA 775/4885MAOB 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.